Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

@article{Komrokji2011ResultsOA,
  title={Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis},
  author={R. Komrokji and M. Wadleigh and J. Seymour and A. Roberts and L. To and H. Zhu and R. Mesa},
  journal={Blood},
  year={2011},
  volume={118},
  pages={282-282}
}
Abstract 282 Background: The JAK2V617F mutation has been linked to the pathogenesis of myeloproliferative neoplasia. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 and the JAK2V617F mutant. In previously reported Phase 1 studies, patients with myelofibrosis (MF) who received pacritinib achieved steady-state plasma levels above the IC50 for JAK2 at all doses (100–600 mg/d). Target inhibition, measured by phosphorylation of the STAT3, STAT5, and JAK proteins in PBMCs and whole… Expand
79 Citations
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
  • C. Keohane, R. Mesa, C. Harrison
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • 2013
Treatment and management of myelofibrosis in the era of JAK inhibitors
Clinical potential of pacritinib in the treatment of myelofibrosis
The New Landscape of Therapy for Myelofibrosis
Therapy with JAK 1/2 inhibitors for myelofibrosis
...
1
2
3
4
5
...